Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
The purpose of this study is to evaluate the clinical benefit of the co-administration of propranolol and etodolac (VT-122 therapy) in patients with clinically progressive prostate cancer.
Prostatic Neoplasms
DRUG: VT-122|DRUG: Placebo
Change in prostate specific antigen (PSA), baseline (Day 1 Cycle 1) to 12 weeks (Day 1, Cycle 4)
PSA progression, baseline to 12 weeks|PSA doubling time (PSADT), baseline and every month during treatment|Change in self-reported performance (EQ-5D), pain (visual analog scale [VAS] and opiate usage), Day 1 Cycle 1, on Day 1 of each subsequent 28-day cycle, and on end of treatment|Time to symptom progression (TTSP), Day 1 Cycle 1 and Day 1 of each subsequent 28-day cycle|Change in correlative biomarkers, Day 1 Cycle 1, on Day 1 of each subsequent 28-day cycle, and on end of treatment
The purpose of this study is to evaluate the clinical benefit of the co-administration of propranolol and etodolac (VT-122 therapy) in patients with clinically progressive prostate cancer.